Additionally, an ongoing phase 3 randomized trial (EXCLAM-2; NCT04129502) evaluated the efficacy of combination treatment with mobiocertinib and platinum-doublet chemotherapy as first-line treatments among patients with treatment-naïve advanced NSCLC whose tumors harbor EGFR ex20ins mutations. Here, EGFR is linked to non-small cell lung carcinoma.